A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
Phase of Trial: Phase I/II
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Nabiximols (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; Proof of concept
- Sponsors GW Pharmaceuticals
- 07 Feb 2017 Top-line results published in a GW Pharmaceuticals media release.
- 10 Aug 2016 Data expected in 4Q of 2016, as per GW Pharmaceuticals media release.
- 10 Aug 2016 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History